Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 2/20 | 0.43 |
| ▸ | CLK2 | P49760 | 2/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.43 |
| ▸ | CLK3 | P49761 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | KIF20A | O95235 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30731156 | 1.00 | CHEK1 (0.49) | CHEK1LRRK2AXLCLK1CLK2 | |
| SCHEMBL19013425 | 0.74 | AXL (0.44) | CHEK1AXLCLK1CLK2CDK5 | |
| SCHEMBL857106 | 0.73 | AXL (0.47) | CHEK1AXLAURKAPARP1GPR84 | |
| SCHEMBL30322758 | 0.70 | AURKA (0.65) | CHEK1LRRK2AXLAURKAPARP1 | |
| SCHEMBL12396544 | 0.70 | AURKA (0.65) | CHEK1LRRK2AXLAURKAPARP1 | |
| SCHEMBL31710926 | 0.69 | LRRK2 (0.48) | CHEK1LRRK2AXLCLK1CLK2 | |
| SCHEMBL23885630 | 0.69 | CHEK1 (0.49) | CHEK1LRRK2CLK1CLK2CDK5 | |
| SCHEMBL21917176 | 0.69 | CHUK (0.50) | CDK5DYRK1ACDK5R1AURKAPARP1 | |
| SCHEMBL4070897 | 0.68 | AURKA (0.45) | AXLDYRK1ADYRK1BAURKAPARP1 | |
| SCHEMBL29621825 | 0.68 | AURKA (0.45) | AXLDYRK1ADYRK1BAURKAPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| EP-3728230-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | Ravenna Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | PIP5K1A, PIP5K1B, PIP5K1C | CHEK1 478/4885LRRK2 259/4885AXL 1942/4885 |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1A, PIP5K1B, PIP5K1C | CHEK1 478/4885LRRK2 259/4885AXL 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.